With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.
GlobalData on MSN1mon
Boehringer seeks approval for lung fibrosis drug following Phase III winBoehringer Ingelheim is seeking regulatory approval for nerandomilast after a Phase III trial in idiopathic pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback